Obesity and associated disorders such as metabolic syndrome and type 2 diabetes (T2D) have reached epidemic proportions. Several natural products have been reported as Peroxisome Proliferator-Activated Receptor (PPAR) agonists, functioning as lead compounds towards developing new anti-diabetic drugs due to adverse side effects of existing PPAR drugs. We recently isolated and identified (7E)-9-oxohexadec-7-enoic acid (1) and (10E)-9-oxohexadec-10-enoic acid (2) from the marine algae Chaetoceros karianus. Herein we report the total synthesis, pharmacological characterization, and biological evaluations of these naturally occurring oxo-fatty acids (oFAs). The syntheses of 1 and 2 afforded sufficient material for extensive biological evaluations. Both oFAs show an appreciable dose-dependent activation of PPARa and -g, with EC 50 values in the micromolar range, and an ability to regulate important PPAR target genes in hepatocytes and adipocytes. Moreover, both 1 and 2 are able to drive adipogenesis when evaluated in the Simpson-Golabi-Behmel syndrome (SGBS) pre-adipocyte cell model, but with lowered expression of adipocyte markers and reduced lipid accumulation compared to the drug rosiglitazone. This seems to be caused by a transient upregulation of PPARg and C/EBPa expression. Importantly, whole transcriptome analysis shows that both compounds induce anti-diabetic gene programs in adipocytes by upregulating insulin-sensitizing adipokines and repressing pro-inflammatory cytokines.
Introduction
Obesity and associated disorders, such as metabolic syndrome and type 2 diabetes (T2D), constitute a serious health problem. The WHO estimates that there are more than 2 billion overweight adults worldwide, half of whom are clinically obese [1] . Over 300 million people suffer from T2D, a number that will continue to grow due to changes in dietary patterns and a more sedentary lifestyle. Understanding the mechanisms of metabolic control in order to prevent and treat these disorders is therefore a top research priority. Present anti-diabetic medications include several drug classes, such as metformin, DPP-4 inhibitors, GLP-1 analogs/ agonists, SGLT-2 inhibitors, as well as drugs targeting the peroxisome proliferator-activated receptors (PPARs).
PPARs are nuclear receptors that heterodimerize with the retinoid X receptor (RXR) and regulate target gene expression in response to lipids such as unsaturated fatty acids, phospholipids, eicosanoids, and oxygenated fatty acids [2] . Upon ligand activation, the PPARs undergo conformational changes that facilitate the dissociation of transcriptional co-repressors like SMRT and NCoR [3, 4] , and recruitment of transcriptional co-activators and coactivator complexes, which include factors such as p300/CBP, SRC-1, and PGC-1a [4, 5] . Additionally, posttranslational modifications alter the structural conformation of the receptors thereby modifying the affinity for co-regulators that determine whether a target gene is induced or repressed. In humans the PPAR isoforms PPARa (NR1C1) and -g (NR1C3) are mainly expressed in liver and adipose tissue, respectively, while PPARd (NR1C2) is more ubiquitously expressed [6, 7] . When PPARg is ligand-activated it induces adipocyte growth and differentiation by transcriptionally regulating target genes involved in lipogenesis and lipid storage [8e10] .
Moreover, activation of PPARg maintains normal insulin sensitivity through upregulation and secretion of adipokines such as adiponectin and leptin from adipose tissue [11] . In parallel, PPARa increases lipid uptake and energy expenditure in liver by upregulating gene targets involved in fatty acid transport, activation and oxidation [12, 13] . We recently identified the two isomeric oxo-fatty acids (7E)-9-oxohexadec-7-enoic acid (1) and (10E)-9-oxohexadec-10-enoic acid (2) from the marine algae Chaetoceros karianus, and demonstrated that they display dual PPAR a/g agonist activity [14] . Several synthetic PPAR drugs are already in clinical use, like the lipid-lowering fibrates, acting as PPARa activators, and the anti-diabetic thiazolidinediones (TZDs), targeting PPARg. However, some of the isoform-specific PPAR agonists like clofibrate, rosiglitazone and pioglitazone have demonstrated adverse effects such as hepatotoxicity [15, 16] , pulmonary edema [17] , myocardial infarction [18] , weight gain [19] , reduced bone density [20] , and bladder and prostate cancer [21, 22] . A suggested way out has been to identify natural products as candidate compounds with potency for both PPARa and -g, aiming at maximizing the beneficial effects, while minimizing the adverse. Several promising dual agonists Scheme 1. Reagents and conditions: (a) (COCl) 2 , DMSO, Et 3 N, CH 2 Cl 2 , 81%; (b) n-BuLi, THF, À78 C, 1ebromohexane; (c) 4, THF, 53% (two steps); (d) Lipase from Pseudomonas cepacia, pH ¼ 7.2, 64%; (e) TBSCl, imidazole, MeCN, 90%; (f) Mg, I 2 cat., THF; (g) (E)-2-octenal, THF, 70% (two steps); (h) TBSCl, imidazole, DMF, 91%; (i) TFA, H 2 O, THF, 65%; (j) DessMartin periodinane, NaHCO 3 , CH 2 Cl 2 ; (k) NaClO 2 , NaH 2 PO 4 , MeCN, 2-methyl-2-butene, H 2 O; (l) TBAF, THF, 67% (three steps); (m) MnO 2 , Celite, CH 2 Cl 2 , 15%. display significant improvement in both glycemic as well as dyslipidemic parameters with no evidence of conventional side effects [23e27] . In this aspect, natural products are of interest. Some natural occurring fatty acid PPAR-agonists are depicted below.
In this paper we report the synthesis, pharmacological characterization, and extensive biological evaluations of the oxofatty acids 1 and 2.
Results and discussion

Chemistry
The synthesis towards (7E)-9-oxohexadec-7-enoic acid (1) started with known methyl 7-hydroxyheptanoate (3) [28, 29] (Scheme 1). Swern oxidation of 3 afforded 4 in 81% yield. Next the commercially available phosphorane 5 was treated with n-BuLi and 1-bromohexane to afford the hexyl substituted intermediate of 5 that was reacted with aldehyde 4 in an E-selective Wittig-reaction. This gave methyl (E)-9-oxohexadec-7-enoate (6) in 53% yield from 3. The hydrolysis of 6 to 1 proved more challenging than anticipated as several conditions failed to produce the natural product 1 due to the formation of polymeric material. However, the acid 1 was formed when 6 was added to a phosphate buffer solution (pH ¼ 7.2, 37 C) containing lipase from Pseudomonas cepacia. The spectral data confirmed the structure of 1 with the E-configuration (J ¼ 15.9 Hz).
The synthetic approach for making 1 was not amendable for making (10E)-9-oxohexadec-10-enoic acid (2) . The a,b-unsaturated ketone moiety in 2 was proven to be quite labile. Hence, an alternative synthetic route was developed. First, known 7 [30] was Fig. 1 . Structure of (7E)-9-oxohexadec-7-enoic acid (1) and (10E)-9-oxohexadec-10-enoic acid (2), (9Z,11E,13S)-13-Hydroxyoctadeca-9,11-dienoic acid (13S-HODE), and (9S,10E,12Z)-9-Hydroxyoctadeca-10,12-dienoic acid (9S-HODE). Fig. 2 . The synthetic oxo-fatty acids (7E)-9-oxohexadec-7-enoic acid (1) and (10E)-9-oxohexadec-10-enoic acid (2) activate PPARa and -g and show low cytotoxicity. Doseresponse of 1 (7E)-9-OHE and 2 (10E)-9-OHE, compared to pirinixic acid, rosiglitazone and palmitic acid on (A) PPARa activity and (B) PPARg activity. The assays were run with Gal4-DBD-NR-LBD chimeric constructs in COS-1 cells, using LBD from human PPARa and PPARg, respectively. (C) Corresponding cytotoxicity data were obtained by measuring lactate dehydrogenase (LDH) in media or (D) by running XTT assays. The results are shown as mean ± SEM. The data represent three biological replicates run in quadruplicates. RLU: relative light units. transferred into its Grignard reagent that was added to a THFsolution of commercially available (E)-2-octenal. This gave the allylic alcohol 8. Hence, alcohol 8 was converted into the bis-TBS ether using standard conditions (TBSCl, imidazole) that was mono-deprotected using aqueous TFA. This gave 9 that was oxidized to the aldehyde using the Dess-Martin reaction. A Lindgren-Pinnick oxidation of the formed aldehyde followed by deprotection of the TBS-group afforded 10. Oxidation of the allylic alcohol was best achieved using electrolytically activated MnO 2 that gave the natural product 2, albeit in 15% yield. The spectral data confirmed the structure of 2. All efforts to improve the yield of 2 were fruitless. The total yield of 2 was 4% over nine steps from 8-bromooctan-1-ol.
Dose-response and toxicity
We started by evaluating oxo-fatty acid (oFA) 1 and 2 with respect to PPARa and PPARg agonist activity using GAL4-LBD fusion constructs and GAL4-responsive Luciferase reporters in COS-1 cells. The oFA activity profile was compared with rosiglitazone and pirinixic acid (positive controls) and palmitic acid (negative control). Cytotoxicity was determined simultaneously assaying for lactate dehydrogenase (LDH) in the cell media. In addition, cytotoxicity was assessed using standard XTT assays. The dose-response curves are shown in Fig. 2 and summarized with corresponding EC 50 values in Table 1 .
As can be seen both oFAs show an appreciable PPAR agonist dose-response, with EC 50 -values in the micromolar range ( Fig. 2 ; Table 1 ). At the same time the cell toxicity, as measured by lactate dehydrogenase leakage (LDH) and reduced metabolic NAD(P)H flux (XTT), is none to moderate in the same concentration range (10e30 mM). With respect to PPARa agonism, both 1 and 2 displayed EC 50 -values and agonist activity comparable to pirinixic acid (WY-1464). However, when assaying 1 and 2 in the PPARg activity assay, their EC 50 -values were approximately 50 fold higher and their PPARg agonist activities about 50% lower of that observed with rosiglitazone (BRL 49653; Fig. 2 ).
Selectivity
We next addressed the selectivity of the two oxo-fatty acids with respect to nuclear receptor agonist activity. To this end we transfected COS-1 cells with GAL4-LBD fusions of human PPARa, -d, -g, LXRa, -b, and RXRa, and treated them with increasing concentrations of the oFAs. Both natural products were able to activate PPARa and -g in the range of 25e50 mM, while neither of them activated the LXRs or RXRa (Fig. 3) . A small but significant PPARd agonist activity was observed with 50 mM of 2.
To be able to study the agonist activity of 1 and 2 in a more relevant context we expressed full-length human PPARa and eg together with RXRa in COS-1 cells and assayed their transactivity on human CPT1A-and PLIN1-driven luciferase reporters in the presence or absence of the oxo-fatty acids. As can be seen in Fig. 4 both 1 and 2 were able to activate the PPARa-target gene promoter CPT1A, while only 1 activated the promoter of PLIN1, a bona fide PPARg target gene. This activation was dependent of functional PPAR response elements (PPREs).
Activation of endogenous PPAR target genes
As both oxo-fatty acids displayed PPAR agonism in vitro, we asked whether 1 and 2 were able to activate fully chromatinized PPAR target genes in the human hepatocellular carcinoma cell line Huh7. Huh7 cells express both PPARa and eg [31] (Ct: 26.3 and 24.6, respectively at baseline), but is often used in combination with PPARa agonist to assess regulation of liver-specific PPARa target genes. While both 1 and 2 were able to induce CPT1A and Fig. 3 . The oxo-fatty acids 1 and 2 display PPARa/g dual specificity. The assays were run with Gal4-DBD-NR-LBD chimeric constructs in COS-1 cells, using the ligand binding domain (LBD) from human nuclear receptors. The doses used were 0, 25 and 50 mM of 1 (7E)-9-OHE and 2 (10E)-9-OHE, respectively. The results are shown as mean ± SEM. The data represent three biological replicates run in quadruplicates. RLU: relative light units. *p < 0.05, **p < 0.05, ***p < 0.001. Fig. 4 . The oxo-fatty acids 1 and 2 activate human natural promoters in a PPAR/ PPRE-depend manner. COS-1 cells were transfected with full-length PPARa, the heterodimerization partner RXRa and a CPT1A-driven reporter, with or without a functional PPAR recognition element (PPRE) or PPARg, RXRa and a PLIN1-driven reporter, with (black bars) or without (white bars) a functional PPRE. The cells were then treated with 1 (7E)-9-OHE or 2 (10E)-9-OHE for 18 h. The results are shown as mean ± SEM. The data represent three biological replicates run in quadruplicates. RLU: relative light units. ***p < 0.001.
ANGPTL4 expression, only 1 activated ACSL3 (Fig. 5) . PLIN1 was only upregulated significantly by 2 but to very low levels. We were surprised to find that ACOX1, a classical PPARa target gene did not respond to any of the treatments. Several of the assayed target genes displayed a weak but significant downregulation (Fig. 5) . Whether this was due to cytotoxic effects were not studied further.
Adipocyte differentiation
Turning our focus to adipocyte-specific target gene activation, we took advantage of the human Simpson-Golabi-Behmel syndrome (SGBS) pre-adipocyte cell line [32] , and differentiated them into adipocytes using an 8 days differentiation protocol as described in the experimental section. On day 8 we either stimulated the cells with 1 or 2, or rosiglitazone. As can be seen in Fig. 6 both 1 and 2 induce the expression of CPT1A, while only 2 was able to upregulate ANGPTL4 expression. Oxo-fatty acid 1 and 2 were not able to induce classical adipocyte markers, such as PLIN1, FABP4 and ADIPOQ. Even rosiglitazone failed to induce these genes any further. The reason for this is probably that differentiated SGBS cells already have a high expression of these genes. As an exception to this, UCP1 was induced 10 times compared to baseline by rosiglitazone.
To address a potential role for 1 and 2 in adipocyte differentiation we compared the adipogenic potential of both compounds to rosiglitazone, by exchanging the classical PPARg agonist with 1, 2 or DMSO the first 4 days of the differentiation protocol. On day 0, 4, 8 and 12 cells were either harvested for RNA isolation, to monitor the expression of target genes, or stained with Oil-Red-O to follow the inclusion of neutral lipids in lipid droplets.
Interestingly both 1 and 2 increased the number of cells with adipocyte-like, multilocular morphology, as well as the total volume of lipid droplets (no. of droplets Â size). As expected, rosiglitazone was much more potent in inducing adipogenesis. Interestingly, the droplets formed during treatment with 1 seemed to be slightly bigger than the ones seen with rosiglitazone and 2 ( Fig. 7, day 12) . To evaluate the gene regulatory events underlying the morphological changes we assayed 20 genes relating to adipogenesis (Fig. 8) , lipid storage and metabolism ( Fig. 9 ) and adipokine signalling and browning ( Fig. 10 ) using quantitative PCR. Both 1 and 2 were able to induce the classical adipogenic factors, PPARG, CEBPA and CEBPB (Fig. 8) . The onset of the adipogenic gene program is also reflected in the upregulation of PLIN1, FABP4, CD36 and SCD1 which play important roles in fatty acid metabolism, transport and storage. This was seen with both oFAs (Fig. 9) . However, the expression of most of these genes seem to be 5e10-fold lower on day 8e12 after stimulation with 25 mM 1 and 2 than with rosiglitazone. This might be related to what seems to be a transient induction of several important adipogenic driver genes when treating the cells with 1 and 2 ( Fig. 8) . Here gene expression peaked at day 4, while the rosiglitazone-treated cells were able to support a stable or increased expression of e.g. PPARG and CEBPA for the whole duration of the experiment. Part of the same pattern can be seen in Fig. 10 with the adipokines and thermogenic factors. Still, it should be noted that both 1 and 2 significantly upregulate the expression of adiponectin (ADIPOQ) and the mitochondrial brown fat uncoupling protein 1 (UCP1) over the 12 day differentiation period (Fig. 10) . 
Adipocyte transcriptomics
To get a comprehensive view of the differential, transcriptional changes occurring during adipocyte differentiation, we sequenced RNA from SGBS cells differentiated for 8 days in medium supplemented with oxo-fatty acid 1, 2 or rosiglitazone. Data from the treated cells were compared to SGBS cells at day 0. As can be seen from the Venn diagrams in Fig. 11A there was a significant overlap between the genes regulated by 1 and 2, with 82.2% among the top 500 upregulated and 85.8% overlap among the top 500 downregulated genes. The overlap between rosiglitazone and the oxofatty acids was 42.0% and 58.4% for the same set of upregulated and downregulated genes, respectively. Pathway enrichment analysis made based on the KEGG collection displayed a significant overrepresentation of upregulated genes involved in e.g. PPAR signalling (hsa03320), fatty acid biosynthesis (hsa00061), and steroid biosynthesis (hsa00100) for 1 and 2, as well as for rosiglitazone (Fig. 11B) . Interestingly, biosynthesis of unsaturated fatty acids and fatty acid elongation (hsa00062 and hsa01041) seem to be overrepresented only in the rosiglitazone gene set. When analysing the downregulated genes, pathways such as extra cellular matrix-receptor interaction (hsa04512), TNF signalling (hsa04668), and AGE-RAGE signalling in diabetic complications (hsa04933) stood out (Fig. 11C) . The principal component analysis made, based on the 8274 differentially expressed genes (DEGs) in our dataset showed that both oxo-fatty acid and rosiglitazone-treated cells differ significantly from the day 0 cells (Fig. 11D) . Interestingly, the transcriptomes from oxo-fatty acid 1 cells cluster with the oxo-fatty acid 2 cells, and separate from the rosiglitazone transcriptomes when the total variance is explained using these principal components. Taking a closer look at the genes in the top tier enriched pathways ( Fig. 12 ) the pattern from the differentiation experiments again becomes evident (Figs. 8e10). Even though both oFAs and rosiglitazone drive the expression of most genes in the sets in the same direction, the potency of 1 and 2 are lower, leading to a gradual decrease in expression and an earlier turning point from up-to downregulation (PPAR signalling) or vice versa (ECM-receptor interaction). The same is also seen for genes involved in fatty acid biosynthesis, adipokine signalling, biosynthesis of unsaturated fatty acids, and AGE-RAGE signalling in diabetic complications (Suppl. Fig. 1 ). In the pathway analysis shown in Fig. 12 and Suppl. Fig. 1 , all genes in the KEGG gene set were included, independent of expression level. To get a better understanding of the difference between the rosiglitazone treated cells and the cells treated with 1 and 2, we plotted the top 500 expressed genes in the rosiglitazone transcriptome in falling order and compared them to the same genes in the oFA transcriptomes (Fig. 13) . Most of the genes express approximately 10-fold lower in the cells treated with 1 and 2, resulting in the veil-like clustering below the rosiglitazone line. Interestingly, ten outliers are easily distinguishable for both treatments ( Fig. 13; red circles) .
A closer look at Table 2 , listing these genes, shows that six out of seven overexpressed genes relate to extra cellular matrix. This probably reflects the more fibroblast-like properties of these cells, and indicates a restricted or delayed adipogenigenesis. The reduced levels of PDK4 and PDE3B point in the same direction (Table 2) . That being said, lower levels of phosphodiesterase 3 might be beneficial as this would lower the anti-lipolytic effect of insulin and enable full induction of UCP1 expression and lipolysis in brown adipocytes in response to adrenergic stimulus [33, 34] .
Our data clearly show that while being able to activate both PPARa and PPARg, oxo-fatty acids 1 and 2 have a reduced were stimulated with either 25 mM 1 (7E)-9-OHE, 25 mM 2 (10E)-9-OHE, or 2 mM rosiglitazone (ROSI) for 24 h. Gene expression was analysed by qPCR using specific SYBR green primers. The results are shown as mean ± SEM. The data represent three biological replicates run in duplicates. *p < 0.05, **p < 0.01, ***p < 0.001.
adipogenic effect compared to rosiglitazone. Even if we corrected for their lower potency by adding twice their EC 50 -values in the stimulation-and differentiation cocktails, their reduced efficacy, especially with respect to PPARg activity (Fig. 2) , restricted gene activation and delayed adipogenigenesis (Figs. 7e10) . This may at first glance be interpreted as a disadvantage. However, as many of the known side effects of the thiazolidinediones (TZDs) have been attributed to their potency and efficacy as classical PPARg-specific agonists, this may in fact be an advantage. The strong adipogenic potential of the TZDs evidently contributes to the weight gain associated with the use of this of this type of anti-diabetic drugs [35, 36] . While 1 and 2 are able to drive adipogenesis, their ability to activate target genes and support lipid storage in adipocytes is several fold lower than that of rosiglitazone (Figs. 7e9) . Whether this is all due to reduced lipid synthesis or also reduced synthesis of lipid droplet coating factors, like the PLIN family (Fig. 14) , is difficult to know.
The continuous increase in expression for many of the PPARg target genes observed with TZD-stimulated adipogenesis (Figs. 9 and 10) has been reported in numerous papers, and is proposed to be caused by these agonists' ability to induce the biosynthesis of endogenous PPARg ligands [37e39]. As unsaturated and elongated Fig. 7 . The oxo-fatty acids 1 and 2 drive adipocyte differentiation, but to a lesser extent than rosiglitazone SGBS cells were differentiated in Quickdiff and 3FC medium for 4 and 8 days, respectively, following standard protocol. The quickdiff medium was supplemented with either 25 mM 1 (7E)-9-OHE, 25 mM 2 (10E)-9-OHE, or 2 mM rosiglitazone. DMSO (0.025%) and BSA (4.2 mM) were used as negative control. Adipocyte differentiation was monitored by staining of neutral lipids using Oil-Red-O. The images are representative for three biological replicates run in duplicates. following standard protocol. The quickdiff medium was supplemented with either 25 mM 1 (7E)-9-OHE, 25 mM 2 (10E)-9-OHE, or 2 mM rosiglitazone. DMSO or DMSO:BSA were used as control. Gene expression was analysed by qPCR using specific SYBR green primers with RNA from cells harvested on day 0, 4, 8, and 12 (D0-D12). The results are shown as mean ± SEM. The data represent minimum 3 biological replicates run in duplicates. *p < 0.05, **p < 0.01, ***p < 0.001. carboxylic acids is the common chemical denominator of the many proposed endogenous PPAR ligands, e.g. PUFAs, prostaglandins and other oxidized eicosanoids, it is intriguing that two of the metabolic pathways necessary to produce such molecules (hsa00062: biosynthesis of unsaturated fatty acids; hsa01041fatty acid elongation) are underrepresented in the top tire DEGs from the oxofatty acid-stimulated cells (Fig. 11) . The oxo-fatty acids, which structurally resemble the linoleic acid metabolites 9S-HODE and 13S-HODE [40] , and even more so the corresponding oxo-fatty acids 9-oxo-ODE and 13-oxo-ODE [41] , are still not able to support a PPAR-driven, self-reinforcing adipogenesis. Whether this is due to 1 and 2 not being able to bind covalently to PPARg as other Fig. 10 . The oxo-fatty acids 1 and 2 induce adipokines and browning factors. SGBS cells were differentiated in Quickdiff and 3FC medium for 4 and 8 days, respectively, following standard protocol. The quickdiff medium was supplemented with either 25 mM 1 (7E)-9-OHE, 25 mM 2 (10E)-9-OHE, or 2 mM rosiglitazone. DMSO or DMSO:BSA were used as control.
Gene expression was analysed by qPCR using specific SYBR green primers with RNA from cells harvested on day 0, 4, 8, and 12 (D0-D12). The results are shown as mean ± SEM. The data represent minimum 3 biological replicates run in duplicates. *p < 0.05, **p < 0.01, ***p < 0.001. a,b-unsaturated ketones [41, 42] or if it a stability issue, should be the focus of future structure-activity-relationship studies.
The reduced PPARg agonistic activity of the oFAs is still strong enough to induce a robust expression of leptin (LEP) and the insulin-sensitizing adipokine adiponectin (ADIPOQ) in the adipocyte model (Fig. 10) . At the same time their PPARa agonistic activity triggers fatty acid catabolism by inducing genes involved in boxidation, like CPT1A and ACSL3 in hepatocytes (Fig. 5) and CPT1A in mature adipocytes (Fig. 6) . This provides the oFAs with additional beneficial effects, known to be inherent properties of other PPARa/ g dual agonists [23, 25, 27, 43] . Certain adipokines contribute to the development of obesity-associated insulin resistance, and studies on the link between obesity and insulin resistance have shown that there is an extensive crosstalk between adipocytes and immune cells in the adipose tissue (AT) [44, 45] . Pro-inflammatory cytokines like IL-6, IL-1b and TNFa are mostly produced and secreted by macrophages infiltrating the AT. However as part of the crosstalk, macrophage-derived factors potently stimulate adipocytes to produce pro-inflammatory cytokines [46e48]. On the other side, activation of PPARg by TZDs is shown to modulate this inflammatory-like state by suppressing cytokine production [49, 50] . Thus, it is agreeable that TNF signaling (hsa04668) is one of the top three overrepresented pathways among the differentially downregulated genes (Fig. 11) . As can be seen in Fig. 15 , both oFAs and rosiglitazone are repressing cytokine production. Interestingly, IL-1b seems to be an exception: only 1 and 2 are able to repress the IL1B gene expression, while rosiglitazone seems to have no effect (Fig. 15) . Since IL-1b is a major pro-inflammatory cytokine involved in AT metainflammation, and known to reduce adipose insulin sensitivity by downregulating IRS1 and GLUT4 expression [51, 52] , it is tempting to suggest that transcriptional regulation of this interleukin 1 B is another potential advantage of the oxo-fatty acids. Indeed IRS2 expression increases with both 1 and 2, while there is a tendency towards increased expression of IRS1 and SLC2A4 (GLUT4) (Fig. 16) .
The adverse effects reported with both PPARa-activating fibrates and PPARg-activating thiazolidinedione, such as hepatotoxicity, pulmonary edema, myocardial infarction, weight gain, reduced bone density, and bladder and prostate cancer [15e22] were not addressed further in this paper. To proceed in this matter we would have to initiate in vivo studies in mice, which given the current in vitro cytotoxicity profile of 1 and 2 was not alternative. Certain of the reported side effects, like cancers of the bladder and prostate, is difficult to detect in animal models. Moreover, clinical trials are often too short to detect drug-related tumorigenesis. Therefore, the carcinogenic potential of most compounds is evaluated based on the extrapolation of minimum 2-year studies in rats or mice. Before testing the oFAs in long term in vivo experiments, less cytotoxic analogues would have to be synthesised and characterized.
Conclusion
Through the synthesis, pharmacological characterization, and biological evaluations of the oxo-fatty acids (7E)-9-oxohexadec-7-enoic acid (1) and (10E)-9-oxohexadec-10-enoic acid (2), we have shown that both compounds are semi-potent dual PPARa/g agonists. While being derived from a marine alga, both oFAs regulate important PPAR target genes in human hepatocytes and adipocytes. Transcriptome analyses show that both compounds activate antidiabetic gene programs in adipocytes by upregulating insulinsensitizing adipokines and repressing pro-inflammatory cytokines. Simultaneously, they do not accumulate lipids in the adipocytes to the same extent as the classical thiazolidinediones. Together these features make the oxohexadecenoic acids interesting molecular scaffolds for designing new ligands with improved stability and a better toxicity profile to test in animal models relevant for T2D and metabolic syndrome.
Experimental section
Chemistry
Methyl 7-hydroxyheptanoate
Methyl 7-hydroxyheptanoate (3) was synthesized using literature protocols [28, 29, 53, 54] . The physical and spectral data of 3 were in full agreement with those reported in the literature.
Methyl (E)-9-oxohexadec-7-enoate (6)
Phosphorane 5 (190 mg, 0.60 mmol, 1.18 equiv.) in THF (4 mL) was added n-BuLi (0.41 mL, 1.6 M in hexane, 1.30 equiv.) at À78 C and stirred for 20 min. 1-Bromohexane (83 mg, 0.51 mmol, 1.00 equiv.) dissolved in CH 2 Cl 2 (0.4 mL) was added dropwise and the solution was allowed to warm up to room temperature overnight. The reaction mixture was diluted with H 2 O (10 mL) and extracted with CH 2 Cl 2 (3 Â 10 mL). The combined organic layers were dried (Na 2 SO 4 ), before being concentrated in vacuo. The crude product was dissolved in CH 2 Cl 2 (1.5 mL) and aldehyde 4 (80 mg, 0.51 mmol, 1.00 equiv.) in CH 2 Cl 2 (1.0 mL) was added. The solution was stirred overnight before being concentrated in vacuo. The crude product was purified by column chromatography on silica (hexanes/EtOAc 9:1) to afford the title compound 6 as a colourless oil. Yield: 75 mg (53%). TLC (hexanes/EtOAc 9:1, KMnO 4 
(E)-9-Oxohexadec-7-enoic acid (1)
The methyl ester 6 (20 mg, 0.07 mmol) was dissolved in phosphate buffer (pH ¼ 7.2, 0.7 mL) and heated to 37 C. Lipase from Pseudomonas cepacia (10 mg) was added and the reaction was stirred at ambient temperature for 24 h. The mixture was and extracted with CH 2 Cl 2 (3 Â 10 mL). The combined organic layers were dried (Na 2 SO 4 ), before being concentrated in vacuo. The crude product was purified by column chromatography on silica (hexanes/EtOAc 97.5:2.5, then 90:10) to afford the title compound 1 as a white solid. Yield: 12 mg (64%). TLC (hexanes/EtOAc 7:3, KMnO 4 stain): R f ¼ 0.12; 
((8-Bromooctyl)oxy) (tert-butyl)dimethylsilane (7)
The compound 7 was prepared essentially as previously reported [30] . 8-Bromooctan-1-ol (6.00 mmol, 1.25 g) was dissolved in dry MeCN (12.0 mL) and added TBSCl (6.3 mmol, 0.94 g) and then imidazole (9.00 mmol, 0.630 g). The mixture was stirred under argon for 1 h. The mixture was filtered, evaporated, and purified by flash chromatography on silica gel (EtOAc:heptane, 49:1) to give the known compound 7 as a colourless oil. Yield 1.74 g (90% 
(E)-16-((Tert-butyldimethylsilyl)oxy)hexadec-6-en-8-ol (8)
Magnesium turnings (6.40 mmol, 0.154 g, 2.00 equiv.) and a magnet were placed in a flame dried round bottomed flask that was flushed with argon. A small amount of iodine (ca. 6 mg) was added. A solution of the bromide 7 (4.16 mmol, 1.34 g, 1.30 equiv.) in dry THF (12.0 mL) was prepared, and about 2 mL of this solution was quickly added to the magnesium turnings. After a few minutes of vigorous stirring, the reaction mixture went from clear brown to colourless. The remaining THF-solution of bromide 7 was then added over 5 min. After 1 h the solution was cloudy and the remaining magnesium was black. The mixture was cooled on an ice bath and added a solution of (E)-2-octenal (3.20 mmol, 0.403 g, 1.00 equiv.) in dry THF (4.00 mL) over 5 min. The cooling bath was removed and the mixture stirred for 1 h. After 1 h, the mixture was cooled on an ice bath and quenched with sat. aq. NH 4 Cl (40 mL). The mixture was extracted with EtOAc (3 Â 20 mL), dried (MgSO 4 ), evaporated and purified by flash chromatography on silica gel (EtOAc:heptane, 15:85) to give the desired product 8 as a colourless oil. Yield: 0.832 g (70%). R f ¼ 0. 35 
(E)-9-((Tert-butyldimethylsilyl)oxy)hexadec-10-en-1-ol (9)
Step 1. Synthesis of (E)-5-(Hept-1-en-1-yl)-2,2,3,3,15,15,16,16-octamethyl-4,14-dioxa-3,15-disilaheptadecane. The alcohol 8 (2.18 mmol, 0.805 g, 1.00 equiv.) was dissolved in dry DMF (10.0 mL) and was added tert-butyl dimethylsilyl chloride (2.62 mmol, 0.394 g, 1.20 equiv.) and imidazole (5.45 mmol, 0.371 g, 2.50 equiv.). After stirring for 16 h, the mixture was added sat. aq. NaHCO 3 (30 mL) and water (50 mL), and the mixture was then extracted with EtOAc (3 Â 30 mL), dried (MgSO 4 ) and evaporated. The residue Step 2. Protected (E)-5-(Hept-1-en-1-yl)-2,2,3,3,15,15,16,16-octamethyl-4,14-dioxa-3,15-disilaheptadecane (1,94 mmol, Fig. 13 . The fatty acids 1 and 2 slow down fibroblast-to-adipocyte transition. Top 500 expressed genes in SGBS cells (day 8) differentiated in medium supplemented with rosiglitazone at was sorted in falling order based on RNA sequencing data (black line). The corresponding expression data from SGBS cells differentiated in medium supplemented with 1 (7E)-9-OHE (A) and 2 (10E)-9-OHE (B) was superimposed on the same graph (grey circles). Outliers are indicated with red circles and gene symbol.
Table 2
Outliers in the Top 500 expressed gene set.
Symbol
Gene name Relative G.E.
Collagen type VI alpha 3 chain þ KRT79
Keratin 79 e PDK4
Pyruvate dehydrogenase kinase 4 e PDE3B Phosphodiesterase 3 B e a Relative to rosiglitazone stimulated SGBS cells. 0,942 g) was dissolved in THF (28 mL) and added a mixture of trifluoroacetic acid in water (4.5 mL, TFA:H 2 O 1:9). The mixture was stirred at ambient temperature for 3 h before it was quenched by addition of sat. aq. NaHCO 3 (50 mL). The mixture was extracted with EtOAc (3 Â 30 mL). The combined organic layer was washed with sat. aq. NaHCO 3 (3 Â 10 mL) and brine (1 Â 10 mL), dried (MgSO 4 ) and evaporated. The residue was purified by flash chromatography (EtOAc:heptane 1:9) to yield the primary alcohol 9 as a colourless oil. Yield: 0.467 g (65% 
(E)-9-Hydroxyhexadec-10-enoic acid (10)
Alcohol 9 (1.53 mmol, 0.566 g, 1.00 equiv.) was dissolved in CH 2 Cl 2 (15.0 mL) and added NaHCO 3 (0.39 g, 3.00 mmol) and DessMartin Periodinane (1.84 mmol, 0.780 g, 1.2 equiv.). The mixture was stirred at room temperature for 1.5 h and then filtered through a plug of silica gel that was washed with a small amount of EtOAc:heptane (1:4). The residue was dissolved in MeCN (15.0 mL) and 2-methyl-2-butene (3.60 mL). Then a solution of NaH 2 PO 4 (6.00 mmol, 0.722 g, 7.00 equiv.) in water (6.00 mL) was added. Finally, 80% NaClO 2 (7.74 mmol, 0.872 g, 9.00 equiv.) was added and the mixture was stirred vigorously for 80 min. Then sat. aq. NaH 2 PO 4 (50 mL) was added and the mixture was extracted with EtOAc (3 Â 20 mL). The combined organic extracts were washed with water (1 Â 10 mL), dried (Na 2 SO 4 ) and evaporated. The resulting residue was taken through a short plug of silica gel eluting with CH 2 Cl 2 :MeOH (19:1). The residue was dissolved in dry THF (5.0 mL) and added a solution of TBAF (10.0 mL, 1.0 M in THF) at 0 C. The mixture was stirred at room temperature overnight. Sat. aq. NaH 2 PO 4 (50 mL) was added and the mixture was extracted with EtOAc (2 Â 30 mL). The combined organic layers were washed with brine, dried (Na 2 SO 4 ) and evaporated. The residue was purified by flash chromatography using a gradient of 5e70% EtOAc in heptane to afford the desired product 10 as a colourless wax. Yield: 156 mg (67%). R f ¼ 0. 46 
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Plasmids
The pSG5-Gal4-hPPARa-LBD, pSG5-Gal4-hPPARd-LBD, and pSG5-Gal4-hPPARg-LBD encoding Gal4 DNA-binding domain (DBD; aa 1-147) fused in frame with the SV40 nuclear localization signal 1 (NLS1), and ligand binding domain (LBD) of human PPARa (aa 168-468), PPARd (aa 140-441), and PPARg (aa 205-505) has been described earlier [14] . pSG-Gal4 encoding Gal4 DBD and SV40 NLS1 was made by amplifying this part of the pSG5-Gal4-hPPARd-LBD, using a custom-made reverse primer that made up the original multi cloning site (MCS): KpnI-XmaI-NotI-EagI-SacII-BamHI-BglII. This PCR product was then subcloned between XhoI and BamHI in pSG5-Gal4-hPPARd-LBD, exchanging PPARd-LBD with the new MCS. pSG5-Gal4-hLXRa-LBD, pSG5-Gal4-hLXRb-LBD, and pSG5-Gal4-hRXRa-LBD encoding Gal4 DBD, SV40 NLS1, and the LBDs of human LXRa (aa 164-447), LXRb (aa 155-461), and RXRa (aa 202-462) were made by PCR amplifying the respective LBDs and subcloning them into pSG-Gal4 between KpnI and BamHI (LXRa and -b) or KpnI and SacII (RXRa). The plasmids encoding FLAG-tagged full-length human PPARa, PPARg, and RXRa have been described earlier [14, 55] . The pGL3-5 Â UAS-SV40 luciferase reporter, as well as the human PLIN1-driven reporters, pGL3-hPLIN1-3 0 del and pGL3-hPLIN1-3 0 del PPREmut, have been described before [9, 14] . The human CPT1A-driven reporters, pGL3-hCPT1AInt and pGL3-hCPT1AInt PPREmut, were received as a gift from Prof. Diego Haro Bautista and have been described previously [56] . The vector pRL-CMV (Promega, Madison, WI), constitutively expressing Renilla Luciferase, was used as a control of transfection efficiency. All cloned plasmids have been sequenced. Cloning primer sequences are available upon request. The Firefly Luciferase readings were normalized to the Renilla Luciferase numbers and data from at least three independent transfection experiments run in quadruplicate are presented. Huh-7 human hepatoma cells were maintained in DMEM (D6546, Sigma-Aldrich) containing penicillin/streptomycin (50 U/ mL; 50 mg/mL), 4 mM L-glutamine, 10% fetal bovine serum (F7524; Sigma-Aldrich), and 0.1% ITS (insulin/transferrin/sodium selenite; I3146, Sigma-Aldrich), at 37 C in a humidified atmosphere of 5% CO 2 in air. Cell confluence never exceeded 80% before subculturing or transfection. The cells were seeded at 2 Â 10 5 cells/well in 12-well plates. After 24 h cells were treated with 50 mM (7E)-9-oxohexadec-7-enoic acid, (10E)-9-oxohexadec-10-enoic acid, or pirinixic acid in DMSO (final conc. 0.1%). On the day after the cells were washed and scraped in RLT buffer (Qiagen, Hilden, Germany). Human Simpson-Golabi-Behmel syndrome (SGBS) cells were cultured and differentiated into adipocytes essentially as described [32] . Briefly, cells were maintained in basal medium (DMEM/ nutrient mix F-12; D6421, Sigma-Aldrich) supplemented with 2 mg/L of biotin, 1 mg/L of D-pantothenate, 4 mM L-glutamine, penicillin/streptomycin (50 U/mL; 50 mg/mL), and 10% noninactivated fetal calf serum (F7524; Sigma-Aldrich). For adipocyte differentiation, cells were seeded at low passage (P6-P8) at 0.8 Â 10 5 cells/well in 12-well plates and grown to confluence (day 0). From day 0 to day 4 the cells were exposed to adipogenic medium (Quickdiff; 3FC supplemented with 25 nM dexamethazone, 0.5 mM isobutylmethylxanthine, and 2 mM rosiglitazone, 25 mM 1 (7E)-9-OHE:BSA, or 25 mM 2 (10E)-9-OHE:BSA, followed by continuous culturing in 3FC (basal medium supplemented with 10 mg/mL human transferrin, 20 nM human insulin, 100 nM cortisol, and 0.2 nM triiodothyronine). Medium was renewed every fourth day. In a set of separate experiments SGBS cells were differentiated with Quickdiff medium, including 2 mM rosiglitazone, from day 0 to day4. Then at day 8 the cells were stimulated with 25 mM 1 (7E)-9-OHE:BSA, 25 mM 2 (10E)-9-OHE:BSA, or 2 mM rosiglitazone in 3FC medium for 24 h.
Cytotoxicity assays
The cytotoxic effect of the compounds were evaluated in COS-1 cells, using the Roche Cytotoxicity Detection Kit (#1164479300, Sigma-Aldrich) measuring lactate dehydrogenase (LDH) leaked from the cells or by the XTT-based In Vitro Toxicology Assay Kit (#TOX2-1 KT, Sigma-Aldrich) measuring reduced metabolic NAD(P) H flux. Both assays were run as described by the company, and absorbance were read at 492/750 nm and 450/690 nm for the LDH and XTT assay, respectively, on a Synergy H1 Hybrid Multi-Mode Microplate Reader (BioTek ® Instruments). RNA was isolated using the RNeasy Mini kit (#74104, Qiagen) with the following modifications: Lysates from cells with high-fat content, such as SGBS cells on day 8 and 12, were mixed 1:1 in 70% ethanol in high salt solution (0.45 M NaCl/0.24 M Na-acetate), before applied to the columns. Isolated RNA (500 ng) was reverse transcribed into cDNA using SuperScript III Reverse Transcriptase (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) and random hexamer primers. qPCR was performed with 2.5 mL cDNA, equivalent to 12.5 ng RNA, in a 10 mL reaction mix using Kapa SYBR FAST qPCR Master Mix (KapaBiosystems, Roche, Basel, Switzerland) on a Bio-Rad CFX96 Touch™ Real-Time PCR Detection System. Gene expression was normalized against the expression of TATA-binding protein (TBP). Assay primers were designed with Primer-BLAST software (NCBI, Bethesda, MD, USA) [57] . Primer sequences are listed in Suppl. Table S1.
RNA-sequencing
SGBS cells were differentiated in Quickdiff and 3FC medium for 4 plus 4 days, respectively, following the protocol described above.
The Quickdiff media was supplemented with either 2 mM rosiglitazone (n ¼ 4), 25 mM 1 (7E)-9-OHE:BSA (n ¼ 4), or 25 mM 2 (10E)-9-OHE:BSA (n ¼ 2). Undifferentiated SGBS cells, grown to confluence (day 0), were also assayed (n ¼ 2). The SGBS cells were lysed in RTL buffer and total RNA extracted using RNeasy Mini kit (Qiagen). RNA quality was assessed on a BioAnalyzer 2100, using the Agilent RNA 6000 Nano Kit (#5067-1511; Agilent Technologies Inc, Santa Clara, CA). The RIN values (RNA integrity number) varied between 9.80 and 10.00, with an average of 9.95. Illumina sequencing libraries were prepared according to the strand-specific TruSeq RNA Sample Preparation Guide (revision D) and sequencing performed on a NextSeq 500 (Illumina, San Diego, CA), using v2 reagents. Libraries were sequenced using 2 Â 75 bp paired-end reads. For prealignment quality control, we used the software FastQC v0.10.1. The mean library size was~18 million read pairs, with no difference between groups or time points. Alignment of cDNA sequenced reads was done using Tophat v2.0.8, Samtools v0.1.18, and Bowtie v2.1.0 with default settings against the UCSC hg19 annotated transcriptome and genome. Reads were counted by Cufflinks v2.1.1 and presented as Reads Per Kilobase of transcript per Million mapped reads (RPKM). Differentially expressed genes were identified using one-way anova and an RPKM cut-off set to 5.
Accession number
Accession number for the RNA-seq data reported in this article is NCBI GEO GSE115827.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software Inc., San Diego, CA, USA). All data are presented as mean and standard error of the mean (SEM) or standard deviation (SD). Statistical differences between groups were determined by two-way analysis of variance (ANOVA) followed by Tukey's multiple comparison tests. For all statistical tests p < 0.05 was considered statistically. Any exceptions to this are given in the Figure legends. 
Venn diagrams
Top 500 differentially expressed genes in our dataset, using mean of replicates, were visualized using the Venn diagram drawing tool from Bioinformatics & Evolutionary Genomics, Ghent University, Belgium (http://bioinformatics.psb.ugent.be/webtools/ Venn).
Principal component analysis
Principal component analysis (PCA) of the 8274 differentially expressed genes in our dataset was made with Clustvis, a web tool for visualizing clustering of multivariate data (https://biit.cs.ut.ee/ clustvis) [58] . Row scaling was made by unit variance scaling (UVS) and missing data imputation was made using singular value decomposition (SVD).
Pathway enrichment analysis
Pathway enrichment analysis of the top 500 differentially upand downregulated genes, using mean of replicates, were made with the ConsensusPathDB tool from the Max-Planck-Institute for Molecular Genetics (http://cpdb.molgen.mpg.de) [59] , using the Kyoto Encyclopedia of Genes and Genomes (KEGG) gene sets v80.0, pathway ID: 00000-05000 excluding non-relevant human diseases. Minimum overlap with input list was set to 3 and the p-value cutoff to p < 0.01.
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